Mono Pharmacare Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Mono Pharmacare has been growing earnings at an average annual rate of 52.9%, while the Healthcare industry saw earnings growing at 29.2% annually. Revenues have been growing at an average rate of 42% per year. Mono Pharmacare's return on equity is 8.7%, and it has net margins of 2%.
Belangrijke informatie
52.9%
Groei van de winst
42.7%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 29.4% |
| Inkomstengroei | 42.0% |
| Rendement op eigen vermogen | 8.7% |
| Nettomarge | 2.0% |
| Laatste winstupdate | 31 Mar 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Opbrengsten en kosten
Hoe Mono Pharmacare geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 24 | 1,224 | 24 | 35 | 0 |
| 31 Dec 23 | 950 | 24 | 32 | 0 |
| 30 Sep 23 | 762 | 22 | 26 | 0 |
| 30 Jun 23 | 547 | 16 | 18 | 0 |
| 31 Mar 23 | 331 | 9 | 10 | 0 |
| 31 Mar 22 | 371 | 4 | 7 | 0 |
| 31 Mar 21 | 284 | 1 | 7 | 0 |
| 31 Mar 20 | 117 | 0 | 10 | 0 |
Kwaliteitswinsten: MONOPHARMA has high quality earnings.
Groeiende winstmarge: MONOPHARMA's current net profit margins (2%) are lower than last year (2.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: MONOPHARMA's earnings have grown significantly by 52.9% per year over the past 5 years.
Versnelling van de groei: MONOPHARMA's earnings growth over the past year (158.8%) exceeds its 5-year average (52.9% per year).
Winst versus industrie: MONOPHARMA earnings growth over the past year (158.8%) exceeded the Healthcare industry 30.6%.
Rendement op eigen vermogen
Hoge ROE: MONOPHARMA's Return on Equity (8.7%) is considered low.